Meet Portia Combow, who has battled Hidradenitis Suppurativa (HS) for nearly two decades. Portia has been generous enough to share her experiences around the stigma, her long journey to diagnosis, as well as her own discovery of disease management strategies. At Thalocan we work to improve the process of disease assessment in clinical research, the patient experience informs all…
To effectively address challenges in clinical trial endpoint management within the immuno-dermatology therapeutic area, a strong team is essential. We are proud to introduce the talented and driven individuals who make up Thalocan Research Innovations. Their expertise and dedication help our customers capture meaningful data to identify treatments that improve patients’ quality of life.
Validating new clinical scales is essential for ensuring data quality and consistent rater assessments. However, the process is often costly, complex, and too critical to leave to chance. Sponsors and research organizations need a reliable Consensus process. Scale development projects are too often abandoned due to timeline and budget constraints. To solve this, Thalocan has…
Accelerating Scale Validation with TAVOS: A Game Changer for Disease Assessment Rater scales have become the standard for measuring endpoints in dermatology clinical research. These instruments are now essential tools for evaluating efficacy in inflammatory skin disease trials. Yet, the process of developing and validating scales remains anything but standard. It is labor-intensive, costly, and…
